Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label relative bioavailability and pharmacokinetics study of aticaprant formulations in healthy adults
NL-OMON50169Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aticaprant in major depressive disorder (MDD) and affective disorder (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Pharmacokinetics. Started Aug 2021; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)affective disorder
Beyond the preview
Go deeper on NL-OMON50169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50169.